Please assess the completion status of the following clinical trial:

Trial Title: A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant has histologically-confirmed adenocarcinoma of the prostate~* The participant has radiographic evidence of metastatic prostate cancer (stage M1 or D2)~* The participant has prostate cancer unresponsive or refractory to hormone therapy (androgen-independent)~* The participant has had disease progression (clinical or radiographic) while receiving docetaxel, or within 120 days of receiving docetaxel-based chemotherapy and in the opinion of the investigator is unlikely to derive significant benefit from additional docetaxel-based therapy, or was intolerant to therapy with this agent~* The participant must have evidence of progressive disease defined as at least one of the following;~  1. Progressive measurable disease: using conventional solid tumor criteria~ 2. Bone scan progression: at least two new lesions on bone scan~ 3. Increasing PSA: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2~* The participant has a PSA ≥ 2 ng/mL~* The participant has prior surgical or medical castration with a serum testosterone of \<50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the participant must be willing to continue the use of LHRH agonists during protocol treatment~* The participant has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2~* The participant has adequate hematologic function (absolute neutrophil count \[ANC\]≥1500/uL, hemoglobin ≥9 g/dL, and platelets ≥100,000/uL)~* The participant has adequate hepatic function (bilirubin ≤ 1.5 times the upper limit of normal (ULN), Aspartate Transaminase (AST) and Alanine Transaminase (ALT) ≤ 3 times the ULN, or ≤ 5 times the ULN if liver metastases are present)~* The participant has adequate renal function (creatinine ≤ 1.5 x ULN or calculated creatinine clearance \> 40 mL/min)~* The participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates ≥ 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate \< 1000 mg of protein in 24 hours to allow participation in the study~* The participant has adequate coagulation function (an international normalized ratio \[INR\] ≤ 1.5 and a Partial Thromboplastin Time \[PTT\] ≤ 5 seconds above the ULN \[unless on oral anticoagulant therapy\]). Participants receiving full-dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (and if on warfarin have a therapeutic INR between 2 and 3)~* The participant has a fasting serum glucose level of \< 160 mg/dL, or below the ULN~Exclusion Criteria:~* The participant has received more than one prior cytotoxic chemotherapy regimen for metastatic disease. (Participants who have had a treatment break followed by a second docetaxel-based regimen with subsequent disease progression are eligible.)~* The participant has received prior therapy with mitoxantrone for advanced prostate cancer (prior adjuvant therapy with mitoxantrone is permitted)~* The participant has a history of symptomatic congestive heart failure or has a pre-study echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) that is ≥ 10% below the LLN~* The participant has received radiotherapy ≤ 21 days prior to first dose of IMC-A12 or Ramucirumab~* The participant is receiving corticosteroids (dexamethasone, prednisone, or others) at a dose \> 5 mg prednisone orally (PO) two times per day (BID) or equivalent. Participants receiving corticosteroids at higher doses may be eligible if their corticosteroid therapy is tapered to study levels (prednisone 5 mg PO BID) prior to first dose of study medication, without concomitant clinical deterioration~* The participant has known or suspected brain or leptomeningeal metastases~* The participant has uncontrolled or poorly controlled hypertension~* The participant has poorly controlled diabetes mellitus. Inclusion Criteria:~* The participant has histologically-confirmed adenocarcinoma of the prostate~* The participant has radiographic evidence of metastatic prostate cancer (stage M1 or D2)~* The participant has prostate cancer unresponsive or refractory to hormone therapy (androgen-independent)~* The participant has had disease progression (clinical or radiographic) while receiving docetaxel, or within 120 days of receiving docetaxel-based chemotherapy and in the opinion of the investigator is unlikely to derive significant benefit from additional docetaxel-based therapy, or was intolerant to therapy with this agent~* The participant must have evidence of progressive disease defined as at least one of the following;~  1. Progressive measurable disease: using conventional solid tumor criteria~ 2. Bone scan progression: at least two new lesions on bone scan~ 3. Increasing PSA: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2~* The participant has a PSA ≥ 2 ng/mL~* The participant has prior surgical or medical castration with a serum testosterone of \<50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the participant must be willing to continue the use of LHRH agonists during protocol treatment~* The participant has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2~* The participant has adequate hematologic function (absolute neutrophil count \[ANC\]≥1500/uL, hemoglobin ≥9 g/dL, and platelets ≥100,000/uL)~* The participant has adequate hepatic function (bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate transaminase \[AST\] and alanine transaminase \[ALT\]≤ 3 times the ULN, or ≤ 5 times the ULN if liver metastases are present)~* The participant has adequate renal function (creatinine ≤ 1.5 x ULN or calculated creatinine clearance \> 40 mL/min)~* The participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates ≥ 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate \< 1000 mg of protein in 24 hours to allow participation in the study~* The participant has adequate coagulation function (an international normalized ratio \[INR\] ≤ 1.5 and a partial thromboplastin time \[PTT\] ≤ 5 seconds above the ULN \[unless on oral anticoagulant therapy\]). Participants receiving full-dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (and if on warfarin have a therapeutic INR between 2 and 3)~* The participant has a fasting serum glucose level of \< 160 mg/dL, or below the ULN~Exclusion Criteria:~* The participant has received more than one prior cytotoxic chemotherapy regimen for metastatic disease. (Participants who have had a treatment break followed by a second docetaxel-based regimen with subsequent disease progression are eligible.)~* The participant has received prior therapy with mitoxantrone for advanced prostate cancer (prior adjuvant therapy with mitoxantrone is permitted)~* The participant has a history of symptomatic congestive heart failure or has a pre-study echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) that is ≥ 10% below the LLN~* The participant has received radiotherapy ≤ 21 days prior to first dose of IMC-A12 or Ramucirumab~* The participant is receiving corticosteroids (dexamethasone, prednisone, or others) at a dose \> 5 mg prednisone orally (PO) two times per day (BID) or equivalent. Participants receiving corticosteroids at higher doses may be eligible if their corticosteroid therapy is tapered to study levels (prednisone 5 mg PO BID) prior to first dose of study medication, without concomitant clinical deterioration~* The participant has known or suspected brain or leptomeningeal metastases~* The participant has uncontrolled or poorly controlled hypertension~* The participant has poorly controlled diabetes mellitus. Participants with a history of diabetes are allowed to participate, provided that their blood glucose is within normal range (fasting \< 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition~* The participant has a known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness with a history of diabetes are allowed to participate, provided that their blood glucose is within normal range (fasting \< 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition~* The participant has a known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone (Type: EXPERIMENTAL): None
- IMC-A12 + Mitoxantrone + Prednisone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete